The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, with an average 5-year survival rate of less than 10%. Unfortunately, the majority of patients have unresectable, locally advanced, or metastatic disease at the time of diagnosis. Moreover, traditional treatments such as chemotherapy, surgery, and radiation have not been shown to significantly improve survival. Recently, there has been a swift increase in cancer treatments that incorporate immunotherapy-based strategies to target all the stepwise events required for tumor initiation and progression. The results in melanoma, non-small-cell lung cancer and renal cell carcinoma are very encouraging. Unfortunately, the application of checkpoint inhibitors, including anti-CTLA4, anti-PD-1, and anti-PD-L1 antibodies, in pancreatic cancer has been disappointing. Many studies have revealed that the PDAC microenvironment supports tumor growth, promotes metastasis and consists of a physical barrier to drug delivery. Combination therapies hold great promise for enhancing immune responses to achieve a better therapeutic effect. In this review, we provide an outline of why pancreatic cancer is so lethal and of the treatment hurdles that exist. Particular emphasis is given to the role of the tumor microenvironment, and some of the latest and most promising studies on immunotherapy in PDAC are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889
Horn, L., Spigel, D. R., Vokes, E. E., Holgado, E., Ready, N., Steins, M., Poddubskaya, E., Borghaei, H., Felip, E., Paz-Ares, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.3062 · Cited by 861
Nywening, T. M., Wang-Gillam, A., Sanford, D. E., Belt, B. A., Panni, R. Z., Cusworth, B. M., Toriola, A. T., Nieman, R. K., Worley, L. A., Yano, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00078-4 · Cited by 807
The role of stroma in pancreatic cancer: Diagnostic and therapeutic implications
Erkan, M., Hausmann, S., Michalski, C. W., Fingerle, A. A., Dobritz, M., Kleeff, J., & Friess, H. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.115 · Cited by 662
Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.
Bethune, G. C., Bethune, D. C. G., Ridgway, N. D., & Xu, Z. (2010) · Europe PMC (PubMed Central) · Cited by 651
Sanford, D. E., Belt, B. A., Panni, R. Z., Mayer, A., Deshpande, A. D., Carpenter, D., Mitchem, J. B., Plambeck-Suess, S. M., Worley, L. A., Goetz, B. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0525 · Cited by 613
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 610
Jaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.145 · Cited by 600
Tumor microenvironment participates in metastasis of pancreatic cancer
Ren, B., Cui, M., Yang, G., Wang, H., Feng, M., You, L., & Zhao, Y. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0858-1 · Cited by 589
Cancer Immunotherapy Comes of Age
Topalian, S. L., Weiner, G. J., & Pardoll, D. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0899 · Cited by 586
Le, D. T., Lutz, E., Uram, J. N., Sugar, E. A., Onners, B., Solt, S., Zheng, L., Diaz, L. A., Donehower, R. C., Jaffee, E. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31829fb7a2 · Cited by 564
Karagiannis, G. S., Poutahidis, T., Erdman, S. E., Kirsch, R., Riddell, R. H., & Diamandis, E. P. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0307 · Cited by 507
Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459
Beatty, G. L., Torigian, D. A., Chiorean, E. G., Saboury, B., Brothers, A., Alavi, A., Troxel, A. B., Sun, W., Teitelbaum, U. R., Vonderheide, R. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1320 · Cited by 456
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
(2011) · New England Journal of Medicine · doi:10.1056/nejmc1107627 · Cited by 428
Biology and management of pancreatic cancer
Ghaneh, P., Costello, E., & Neoptolemos, J. P. (2008) · Postgraduate Medical Journal · doi:10.1136/gut.2006.103333 · Cited by 418
Gemcitabine resistance in pancreatic ductal adenocarcinoma
Binenbaum, Y., Na’ara, S., & Gil, Z. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.002 · Cited by 414
Cheng, L., Lopez-Beltran, A., Massari, F., MacLennan, G. T., & Montironi, R. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.104 · Cited by 407
Eric, L., Yeo, C. J., Lillemoe, K. D., Biedrzycki, B., Kobrin, B., Herman, J., Sugar, E., Piantadosi, S., Cameron, J. L., Solt, S., et al. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e3181fd271c · Cited by 403
Thomas, A. M., Santarsiero, L. M., Lutz, E. R., Armstrong, T. D., Chen, Y.-C., Huang, L.-Q., Laheru, D. A., Goggins, M., Hruban, R. H., & Jaffee, E. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031435 · Cited by 347
Dijkgraaf, E. M., Heusinkveld, M., Tummers, B., Vogelpoel, L. T. C., Goedemans, R., Jha, V., Nortier, J. W. R., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3542 · Cited by 346
Laheru, D., Lutz, E., Burke, J., Biedrzycki, B., Solt, S., Onners, B., Tartakovsky, I., Nemunaitis, J., Le, D., Sugar, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0371 · Cited by 346
Pancreatic cancer: why is it so hard to treat?
Oberstein, P. E., & Olive, K. P. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13478680 · Cited by 340
Exocrine pancreatic cancer: Symptoms at presentation and their relation to tumour site and stage
the PANKRAS II Study Group, Porta, M., Fabregat, X., Malats, N., Guarner, L., Carrato, A., de Miguel, A., Ruiz, L., Jariod, M., Costafreda, S., et al. (2005) · Clinical and Translational Oncology · doi:10.1007/bf02712816 · Cited by 272
Molecular Pathogenesis of Pancreatic Cancer
Grant, T. J., Hua, K., & Singh, A. (2016) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2016.09.008 · Cited by 237
Aglietta, M., Barone, C., Sawyer, M. B., Moore, M. J., Miller, W. H., Bagalà, C., Colombi, F., Cagnazzo, C., Gioeni, L., Wang, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu205 · Cited by 219
Jaffee, E. M., Hruban, R. H., Canto, M., & Kern, S. E. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00093-4 · Cited by 215
Therapeutic strategies targeting cancer stem cells
Yoshida, G. J., & Saya, H. (2016) · Cancer Science · doi:10.1111/cas.12817 · Cited by 214
Current progress in immunotherapy for pancreatic cancer
Foley, K., Kim, V., Jaffee, E., & Zheng, L. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.020 · Cited by 203
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Kamath, S. D., Kalyan, A., Kircher, S., Nimeiri, H., Fought, A. J., Benson, A., & Mulcahy, M. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0473 · Cited by 194
Update on the management of pancreatic cancer: Surgery is not enough
Ansari, D., Gustafsson, A., & Andersson, R. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i11.3157 · Cited by 180
Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent
Mayo, S. C., Nathan, H., Cameron, J. L., Olino, K., Edil, B. H., Herman, J. M., Hirose, K., Schulick, R. D., Choti, M. A., Wolfgang, C. L., et al. (2012) · Cancer · doi:10.1002/cncr.26553 · Cited by 164
Foucher, E. D., Ghigo, C., Chouaïb, S., Galon, J., Iovanna, J., & Olive, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01044 · Cited by 145
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma
Samuel, N., & Hudson, T. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.215 · Cited by 136
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 132
Karakhanova, S., Link, J., Heinrich, M., Shevchenko, I., Yang, Y., Hassenpflug, M., Bunge, H., von Ahn, K., Brecht, R., Mathes, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.998519 · Cited by 118
Therapeutic use of anti-CTLA-4 antibodies
Blank, C. U., & Enk, A. (2014) · International Immunology · doi:10.1093/intimm/dxu076 · Cited by 116
Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Şahin, İ. H., Askan, G., Hu, Z., & O'Reilly, E. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx503 · Cited by 115
Amedei, A., Niccolai, E., Benagiano, M., Bella, C. D., Cianchi, F., Bechi, P., Taddei, A., Bencini, L., Farsi, M., Cappello, P., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1429-3 · Cited by 109
Pancreatic cancer microenvironment: a current dilemma
Uzunparmak, B., & Şahin, İ. H. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0221-1 · Cited by 105
Large, T. Y. S. L., Bijlsma, M. F., Kazemier, G., van Laarhoven, H. W. M., Giovannetti, E., & Jiménez, C. R. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.008 · Cited by 97
Khorana, A. A. (2012) · American Journal of Hematology · doi:10.1002/ajh.23143 · Cited by 87
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications
Santoni, M., Massari, F., Nunno, V. D., Conti, A., Cimadamore, A., Scarpelli, M., Montironi, R., Liang Cheng, C., Battelli, N., & Antonio Lopez-beltran, B. (2018) · Drugs in Context · doi:10.7573/dic.212528 · Cited by 86
Immunotherapy in pancreatic cancer treatment: a new frontier
Thind, K., Padrnos, L. J., Ramanathan, R. K., & Borad, M. J. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16667909 · Cited by 85
Radiation Therapy and Immunotherapy: What is the Optimal Timing or Sequencing?
Aliru, M. L., Schoenhals, J. E., Venkatesulu, B. P., Anderson, C., Barsoumian, H. B., Younes, A. I. A., Mahadevan, L. S. K., Soeung, M., Aziz, K. E., Welsh, J. W., et al. (2018) · Immunotherapy · doi:10.2217/imt-2017-0082 · Cited by 84
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities
Young, K., Hughes, D. J., Cunningham, D., & Starling, N. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918816281 · Cited by 71
Mahmood, J., Shukla, H. D., Soman, S., Samanta, S., Singh, P., Kamlapurkar, S., Saeed, A. M., Amin, N. P., & Vujašković, Ž. (2018) · Cancers · doi:10.3390/cancers10120469 · Cited by 68
Liu, Q., Li, Y., Niu, Z., Zong, Y., Wang, M., Yao, L., Lu, Z., Liao, Q., & Zhao, Y. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0304-4 · Cited by 63
PD-L1 Expression in Pancreatic Cancer
Zheng, L. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw304 · Cited by 62
Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer
Zhang, J., Wolfgang, C. L., & Zheng, L. (2018) · Cancers · doi:10.3390/cancers10020039 · Cited by 56
Molecular Pathology of Pancreatic Cancer: From Bench-to-Bedside Translation
Corbo, V., Tortora, G., & Scarpa, A. (2012) · Current Drug Targets · doi:10.2174/138945012800564103 · Cited by 54
Cheng, X., Kim, J. Y., Ghafoory, S., Duvaci, T., Rafiee, R., Theobald, J., Alborzinia, H., Holenya, P., Fredebohm, J., Merz, K., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.01.008 · Cited by 51
Human Pancreatic Cancer Stem Cells: Implications for How We Treat Pancreatic Cancer
Lee, C. J., Li, C., & Simeone, D. M. (2008) · Translational Oncology · doi:10.1593/tlo.08013 · Cited by 46
Metformin and pancreatic cancer: Is there a role?
Souza, A. O., Khawaja, K. I., Masud, F., & Saif, M. W. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2948-8 · Cited by 45
(2013) · Europe PMC (PubMed Central) · Cited by 43
Parente, P., Parcesepe, P., Covelli, C., Olivieri, N., Remo, A., Pancione, M., Latiano, T. P., Graziano, P., Maiello, E., & Giordano, G. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/7530619 · Cited by 40
Cited by
Cell death in pancreatic cancer: from pathogenesis to therapy
Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00486-6 · Cited by 336
Lander, V. E., Belle, J. I., Kingston, N. L., Herndon, J. M., Hogg, G. D., Liu, X., Kang, L.-I., Knolhoff, B. L., Bogner, S. J., Baer, J. M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0192 · Cited by 114
Targeting DNA damage repair pathways in pancreas cancer
Crowley, F., Park, W., & O’Reilly, E. M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09983-1 · Cited by 43
Metadata
- Authors
- Sarantis, P., Koustas, E., Papadimitropoulou, A., Papavassiliou, A. G., & Karamouzis, M. V.
- Venue
- World Journal of Gastrointestinal Oncology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2020-02-15
- Volume
- 12
- Issue
- 2
- Pages
- 173-181
- ISSN
- 1948-5204 (ISSN-L)
- OpenAlex
- W3005976323
- Cited by
- 472
- References
- 70
- FWCI
- 15.64
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.